Ongoing

4

315

Europe

Methotrexate, Sulfasalazine, Leflunomide, Humira, N/A, Tablet, Injection, Methotrexate, Salazopyrin EN, Arava, Humira

University of Oxford, NIHR

Physical Inactivity , Poor dietary behaviour , Obesity , Overweight

 

 

Completed

4

300

 

Qiangji Granule placebo, Sulfasalazine, Ibuprofen ;Qiangji Granule placebo, Sulfasalazine, Ibuprofen

School of Chinese Medicine Southern Medical University; Development and Reform Commission of Guangdong Province, the

ankylosing spondylitis

 

 

Ongoing

4

535

Europe

Methotrexate, Prednisone, Sulfasalazine, hydroxychloroquine, adalimumab, MTX, HCQ, hydroxychloroquine, Humira, hydroxychloroquine, Humira

Leiden University Medical Center, department of rheumatology

rheumatoid arthritis and undifferentiated arthritis

 

 

Ongoing

4

190

Europe

Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine, Methotrexate, Sulfasalazine, Hydroxychloroquine, Ciclosporin, Leflunomide, Sodium aurothiomalate (intramuscular gold), methylprednisolone, Prednisolone, Infliximab, Etanercept, Adalimumab, Azathioprine, Penicillamine,

King\'s College London

Rheumatoid Arthritis

 

 

Not yet recruiting

4

106

Europe

Benepali, Etanercept, Sulfasalazine, Methotrexate, Hydroxychloroquine

University of Leeds, Samsung Bioepis Co., Ltd.

Rheumatoid Arthritis

02/23

02/23

Recruiting

4

315

Europe

Methotrexate, Sulfasalazine, Leflunomide, Adalimumab

University of Oxford

Psoriatic Arthritis

08/24

02/25

Not yet recruiting

4

1000

 

None ;Adalimumab tapering combined with methotrexate therapy. The recommended dosage of adalimumab is as follows: Adalimumab, 40 mg/2 weeks, subcutaneous injection, reduce the dose after full dose treatment after reaching low disease activity. The dose reduction is carried out as follows: to extend the duration of administration and limiting the maximum duration of administration interval to 6 weeks (it is recommended to extend the duration of administration interval to 3, 4 or 6 weeks). The recommended dose of methotrexate is as follows: Methotrexate, taken orally, 10-30 mg once a week. ;triple therapy is applied. According to the patient's condition and willingness of patients, three traditional synthetic anti-rheumatic drug combination treatment could be applied, including but not limited to: methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, etc. Recommended usage and dosage are as follows: Methotrexate, oral, 10-30 mg each time, once a week; Leflunomide, 10-20 mg once daily; Sulfasalazine, orally, 500 mg-1,000 mg each time, 3-4 times a day; Hydroxychloroquine, orally, 0.2 g to 0.4 g, once a day.

The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Self-funded

rheumatoid arthritis

 

 

Ongoing

3

20

Europe

Sulfasalazine, Gemcitabine,

Universitätsklinikum Schleswig-Holstein

Pancreatic ductal adenocarcinoma, non resectable

 

 

Recruiting

3

50

RoW

Sulfasalazine

Tanta University

Metastatic Colorectal Cancer

09/25

09/26

Recruiting

3

270

Europe

Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara

University of Erlangen-Nürnberg Medical School

Psoriatic Arthritis, Withdrawal, Reduction

10/24

10/25

Not yet recruiting

2

38

 

Australian Genomic Cancer Medicine Centre Ltd t/a Omico, Cancer Institute NSW

Pancreatic cancer

 

 

Recruiting

2

42

US

Sulfasalazine, Azulfidine, Placebo

Brigham and Women's Hospital

Primary Sclerosing Cholangitis

09/24

11/24

Not yet recruiting

2

20

NA

Sulfasalazine Tablets

Qiong Fu

Systemic Lupus Erythematosus

05/25

05/25

Completed

2

10

US

Sulfasalazine, Active treatment, Placebos, Non-active

University of Arizona

Breast Cancer, Chronic Pain Due to Malignancy (Finding)

10/23

10/23

Recruiting

1/2

80

RoW

Sulfasalazine, Ambrisentan, Sulfasalazine's placebo, Ambrisentan's placebo

RenJi Hospital

Pulmonary Arterial Hypertension

12/21

10/22

Recruiting

1/2

120

Europe

Gabapentin, Sulfasalazine, Memantine, Temozolomide, Radiotherapy

University of Zurich, Swiss National Science Foundation

Glioblastoma

06/26

12/26

Completed

1

30

US

Methotrexate, Leucovorin, BMS-986371, CC-99677, Sulfasalazine

Bristol-Myers Squibb

Healthy Participants

11/22

11/22

Not yet recruiting

1

82

 

Sulfasalazine + parisgut oral treatment; Thunder-fire moxibustion treatment was given based on the control group

Beijing Luhe hospital Affiliated to Capital Medical University; Beijing Municipal Commission of Health, Beijing Municipal Commission of Health

acute radiation enteritis after pelvic tumor radiotherapy

 

 

Completed

N/A

10

US

CapScan intestinal sampling device

Envivo Bio Inc, National Cancer Institute (NCI)

Healthy

10/22

10/22

Recruiting

N/A

330

RoW

Sulfasalazine enteric-coated tablets

The Second Affiliated Hospital of Chongqing Medical University

Cirrhosis, Liver, Fibrosis, Liver

10/28

10/28

Not yet recruiting

N/A

70

 

Follow up every 12 weeks to evaluate the Treatment to Target. If not reach the target, first increase the TNFi dose to the standard dose, and then adjust the csDMARDs (including methotrexate, Tripterygium wilfordii, Iguratimod, leflunomide, hydroxychloroquine, and sulfasalazine); If reach the target, the TNFi was reduced and maintained until the maintenance dose was achieved. The order of reduction was YSP/ETA 50mg QW, 25mg QW, 25mg Q2W (maintenance dose), ADA 40mg Q2W, Q3W, Q4W (maintenance dose), and csDMARDs remained unchanged.; Follow up every 12 weeks to evaluate the Treatment to Target. If not reach the target, first increase the TNFi dose to the standard dose, and then adjust the csDMARDs (including methotrexate, Tripterygium wilfordii, Iguratimod, leflunomide, hydroxychloroquine, and sulfasalazine); If reach the target, the TNFi was reduced and maintained until the maintenance dose was achieved. The order of reduction was YSP/ETA 50mg QW, 25mg QW, 25mg Q2W (maintenance dose), ADA 40mg Q2W, Q3W, Q4W (maintenance dose), and csDMARDs remained unchanged.

Beijing Hospital; Beijing Hospital, National High Level Hospital Clinical Research Funding

rheumatoid arthritis

 

 

Recruiting

N/A

2000

US

Methotrexate, Sulfasalazine, Azulfidine, Leflunomide, areva, Pamidronate, Aredia, Zoledronic acid, Etanercept, enbrel, Adalimumab, humira, Certolizumab, cimzia, Infliximab, remicade, inflectra, Golimumab, simponi, NSAID

Seattle Children's Hospital, Boston Children's Hospital, Boston, MA, USA, Hospital for Special Surgery, New York, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, Riley Children's Hospital, Indianapolis, IN, USA, University of North Carolina, Chapel Hill, NC, USA, Royal Children's Hospital, Melbourne, Australia, Hacettepe University, Ankara, Turkey, Bambino Gesù Children's Hospital, Rome, Italy, University of British Columbia, Vancouver, BC, Canada, Meyer Children's Hospital, Florence, Italy, Mansoura University, University of Utah, Salt Lake City, UT, USA, University of Iowa Carver College of Medicine, Iowa City, IA, USA, Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA, Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK, University of Calgary, Calgary, Alberta, Canada

Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis

08/28

08/50